Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.47%77 Capex-to-Operating-Income is 0.25 as of Mar. 2026, which is 56% above its 10-year median of 0.16. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 399 Medical Devices & Instruments companies, Coloplast AS ranks better than 78.7% on this metric.
Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Coloplast AS (OTCPK:CLPBY) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
Coloplast AS Capex-to-Operating-Income Related Terms
Coloplast AS Capex-to-Operating-Income Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Capex-to-Operating-Income Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Capex-to-Operating-Income vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Capex-to-Operating-Income falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Income of 0.25 mean?
Coloplast AS (CLPBY) has a Capex-to-Operating-Income of 0.25 as of Mar. 2026. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Coloplast AS and its competitors. This is 56% above median its historical median of 0.16. Over the past decade, Coloplast AS's Capex-to-Operating-Income has ranged from 0.11 to 0.31. According to the industry distribution chart, Coloplast AS ranks #85 out of 399 companies in the Medical Devices & Instruments industry, placing it in the top 21.3%.
Is Coloplast AS's Capex-to-Operating-Income too high?
Coloplast AS's current Capex-to-Operating-Income of 0.25 is 56% above median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.31. The Medical Devices & Instruments industry median Capex-to-Operating-Income is 0.47. Coloplast AS's value of 0.25 is 46.8% below this industry median. Based on the distribution chart, Coloplast AS ranks #85 out of 399 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Capex-to-Operating-Income compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #85 out of 399 companies for Capex-to-Operating-Income. This places Coloplast AS in the top 21% of its industry — outperforming the majority of peers. The industry median Capex-to-Operating-Income is 0.47. Coloplast AS's value of 0.25 is 46.8% below this benchmark. Historically, Coloplast AS's own Capex-to-Operating-Income has ranged from 0.11 to 0.31 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 0.47, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Income for a Medical Devices & Instruments company?
The median Capex-to-Operating-Income among Medical Devices & Instruments companies is 0.47, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Income significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Capex-to-Operating-Income of 0.25 is 46.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Income mean?
A high Capex-to-Operating-Income can signal that a stock is expensive relative to its fundamentals. Capex to Operating Income ratio measures a company's investments in physical assets to its operating income. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Capex-to-Operating-Income is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Capex-to-Operating-Income is 0.25, which is 56% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.70 — trading 48.7% below its estimated fair value. The current Capex-to-Operating-Income is 0.25, which is 56% above median its 10-year median of 0.16 and 46.8% below the Medical Devices & Instruments industry median of 0.47. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Income calculated?
Capex-to-Operating-Income is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Capex-to-Operating-Income is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.70 is trading 48.7% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Capex-to-Operating-Income: 0.25 (56% above median its 10-year median of 0.16)
GF Value™: $13.05 vs. price of $6.70 (48.7% below fair value)
Industry Position: 46.8% below the Medical Devices & Instruments median (#85 of 399)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Capex-to-Operating-Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
